From Wikipedia, the free encyclopedia
Content deleted Content added
|
|
|||
| Line 15: | Line 15: | ||
|
| education = |
| education = |
||
|
| occupation = |
| occupation = |
||
|
| known for = Founder, CEO, chairwoman and president of Akeso |
| known for = Founder, CEO, chairwoman and president of Akeso |
||
|
| title = |
| title = |
||
|
| term = |
| term = |
||
| Line 29: | Line 29: | ||
|
}} |
}} |
||
|
”’Michelle Xia”’ (Chinese: {{lang|zh-hans|夏瑜}}; born 1966 or 1967) is a Chinese biopharmaceutical executive. She founded Akeso |
”’Michelle Xia”’ (Chinese: {{lang|zh-hans|夏瑜}}; born 1966 or 1967) is a Chinese biopharmaceutical executive. She founded Akeso in 2012 and serves as the company’s chairwoman, president, and chief executive officer.<ref name=”AR20242″>{{cite web |date=30 March 2025 |title=Annual Report 2024 |url=https://www.akesobio.com/media/2563/24ar.pdf |access-date=14 November 2025 |publisher=Akeso, Inc. |page=37}}</ref><ref name=”HKEX2″>{{cite web |date=14 April 2020 |title=Global Offering (Prospectus) |url=https://www1.hkexnews.hk/listedco/listconews/sehk/2020/0414/2020041400145.pdf |access-date=14 November 2025 |publisher=Hong Kong Exchanges and Clearing}}</ref> |
||
|
== Early life and education == |
== Early life and education == |
||
Latest revision as of 08:48, 23 November 2025
Chinese billionaire businesswoman
|
Michelle Xia |
|
|---|---|
| Born |
Xia Yu 1966 or 1967 (age 58–59)[1] |
| Known for | Founder, CEO, chairwoman and president of Akeso |
Michelle Xia (Chinese: 夏瑜; born 1966 or 1967) is a Chinese biopharmaceutical executive. She founded Akeso in 2012 and serves as the company’s chairwoman, president, and chief executive officer.[2][3]
Early life and education
[edit]
Xia was born in Gansu province.[4] She is the daughter of two university-educated engineers.[1]
She earned a degree in biochemistry from Sun Yat-sen University in Guangzhou in 1988, and a doctorate in molecular biology and microbiology from Newcastle University in the UK.[1] She also undertook postgraduate study at the University of Glasgow.[5] In 1996, she moved to the United States to conduct cancer research at the University of Louisville.[1]
Xia co‑founded Akeso in 2012 and has served as chairwoman, president and CEO since inception.[2] The company listed on the Main Board of the Hong Kong Stock Exchange in April 2020.[3] Earlier in her career she held scientific or leadership roles at Crown Bioscience, PDL BioPharma, and Bayer.[6] Since 2023, she has served on the board of Summit Therapeutics.[7]
Under Xia, Akeso have developed Ivonescimab, which appears to outperform Pembrolizumab (marketed as Keytruda), produced by Merck in the US.[4]
In March 2025, she was included in the “TIME100 Health” list.[8]
As of July 2025, Forbes estimates her net worth at US$1.2 billion.[1]
